In line with this, the expanding complexity of drug advancement, notably in areas like oncology and uncommon health conditions, necessitates more substantial and more complex phase III trials. This complexity contains the necessity for specialized supplies, patient-centric strategies, and adaptive trial types. Furthermore, the demand from customers